Dopamine D3 Receptor Antagonists. 1. Synthesis and Structure−Activity Relationships of 5,6-Dimethoxy-N-alkyl- and N-Alkylaryl-Substituted 2-Aminoindans
- 17 November 2001
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 44 (26) , 4716-4732
- https://doi.org/10.1021/jm010145w
Abstract
5,6-Dimethoxy-2-(N-dipropyl)-aminoindan (3, PNU-99194A) was found to be a selective dopamine D3 receptor antagonist with potential antipsychotic properties in animal models. To investigate the effects of nitrogen substitution on structure−activity relationships, a series of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans were synthesized and evaluated in vitro for binding affinity and metabolic stability. The results indicate that substitution at the amine nitrogen of the 2-aminoindans is fairly limited to the di-N-propyl group in order to achieve selective D3 antagonists. Thus, combinations of various alkyl groups were generally inactive at the D3 receptor. Although substitution with an N-alkylaryl or N-alkylheteroaryl group yields compounds with potent D3 binding affinity, the D2 affinity is also enhanced, resulting in a less than 4-fold preference for the D3 receptor site, and no improvements in metabolic stability were noted. A large-scale synthesis of the D3 antagonist 3 has been developed that has proven to be reproducible with few purification steps. The improvements include the use of 3,4-dimethoxybenzaldehyde as a low-cost starting material to provide the desired 5,6-dimethoxy-1-indanone 5c in good overall yield (65%) and the formation of a soluble silyl oxime 17 that was reduced efficiently with BH3·Me2S. The resulting amino alcohol was alkylated and then deoxygenated using a Lewis acid and Et3SiH to give the desired product 3 in good overall yield of (∼65%) from the indanone 5c.Keywords
This publication has 17 references indexed in Scilit:
- Neurotransmitter interactions in schizophrenia—therapeutic implicationsBiological Psychiatry, 1999
- PNU‐99194A: A Preferential Dopamine D3 Receptor AntagonistCNS Drug Reviews, 1998
- Linking the Family of D2 Receptors to Neuronal Circuits in Human Brain: Insights into SchizophreniaNeuropsychopharmacology, 1997
- Induction of c-fos mRNA in Rat Medial Prefrontal Cortex by Antipsychotic Drugs: Role of Dopamine D2 and D3 ReceptorsCerebral Cortex, 1996
- Effects of dopamine D3 preferring compounds on conditioned place preference and intracranial self-stimulation in the ratJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1995
- substituted (S)-Phenylpiperidines and Rigid Congeners as Preferential Dopamine Autoreceptor Antagonists: Synthesis and Structure-Activity RelationshipsJournal of Medicinal Chemistry, 1994
- Dopamine receptor pharmacologyTrends in Pharmacological Sciences, 1994
- The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activityJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1993
- Dopamine D2 receptor binding properties of [3H]U-86170, a dopamine receptor agonistEuropean Journal of Pharmacology, 1991
- Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylaseNature, 1990